WHO is developing its first global guideline on prevention, diagnosis and management of delirium in older adults, with medication safety and deprescribing as named parts. The evidence reviews will use strict trial-based methods, yet past drug trials enrolled few people with prior thinking problems, which limits direct guidance for mild cognitive impairment (MCI).
Delirium is a sudden change in attention and awareness, often triggered by illness, surgery or drugs. Deprescribing means carefully lowering or stopping a risky drug under clinical supervision. MCI means early memory or thinking change that does not remove daily independence.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What will WHO cover in 2026?
- How will WHO judge drug evidence?
- Why is evidence thin for MCI?
- Which medicines draw caution now?
What will WHO cover in 2026?
WHO lists prevention, diagnosis and management of delirium in older adults as the scope, explicitly including medication safety and deprescribing, according to the WHO call for experts. That wording matters for families because drugs are a preventable contributor.
WHO contracted a guideline methodologist to run GDG Session 0 and set up the evidence-review process. Applications were due 7 Oct 2026, with work in Oct-Dec 2026 and 2027. The schedule signals a full guideline process, not a quick advice sheet.
How will WHO judge drug evidence?
WHO guideline development requires commissioned systematic reviews, preferably of randomized trials framed by PICO, with GRADE certainty rated high, moderate, low or very low, according to the WHO Handbook for Guideline Development. PICO frames each question by patient group, treatment, comparison and outcome.
That design favors clear drug comparisons with control groups. It also discounts low-certainty or observational findings when setting strong advice. For MCI families, a recommendation may therefore stay cautious even when concern about a drug is high.
Why is evidence thin for MCI?
Past delirium drug trials rarely enrolled people with prior cognitive impairment. A systematic review found only about 18 percent of prevention-trial and 2 percent of treatment-trial participants had pre-existing cognitive impairment or dementia, according to the systematic review. That gap limits direct proof for people with MCI. WHO's updated dementia risk-reduction guidance covers adults without dementia including normal cognition or MCI and recommends cognitive training and vascular-risk management.
It does not replace delirium drug guidance. Readers should not assume risk-reduction steps prevent drug-induced delirium. A large 2025 cohort compared 11,678 trazodone users with 29,590 atypical-antipsychotic users aged 65 and older treated after delirium admission. Trazodone was linked with lower rehospitalization and all-cause mortality than quetiapine, risperidone or olanzapine, but the authors warned residual bias cannot be excluded because the study was observational.
Which medicines draw caution now?
The American Geriatrics Society guideline strongly recommends avoiding benzodiazepines, anticholinergics such as diphenhydramine, and meperidine after surgery, but rates the supporting evidence as low quality. Low quality does not mean low risk. It means trial proof is weak while clinical concern remains.
The NICE delirium summary does not support routine benzodiazepines or antipsychotics. It reserves short-term haloperidol only when a patient poses danger and non-drug measures failed. Families can use that boundary to ask whether a drug is routine or rescue use.
- Bring a full list of prescriptions, sleep aids, allergy drugs and pain drugs to each visit
- Ask which drug can be lowered, paused or replaced, and what withdrawal signs to watch
- Ask about non-drug steps for sleep, pain, anxiety and agitation first
- Track attention, alertness and new confusion for 24 to 72 hours after any drug change
You Might Also Like
- The Long-Term Care Data Cooperative and Dementia Research in 2026: What the Findings Mean for People With Mild Cognitive Impairment
- NHATS and NSOC Dementia Care Data Priorities in 2026: What the Findings Mean for People With Mild Cognitive Impairment
- Electronic Health Records for Dementia Care Research in 2026: What the Findings Mean for People With Mild Cognitive Impairment
